The estimated Net Worth of Bhatnagar Anish is at least $55.4 Milion dollars as of 28 August 2024. Anish Anish owns over 115,004 units of Soleno Therapeutics Inc stock worth over $36,006,816 and over the last 7 years he sold SLNO stock worth over $18,579,329. In addition, he makes $822,089 as President, Chief Executive Officer a Director at Soleno Therapeutics Inc.
Anish has made over 11 trades of the Soleno Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 115,004 units of SLNO stock worth $5,454,640 on 28 August 2024.
The largest trade he's ever made was selling 127,344 units of Soleno Therapeutics Inc stock on 5 August 2024 worth over $5,806,886. On average, Anish trades about 20,978 units every 35 days since 2018. As of 28 August 2024 he still owns at least 741,186 units of Soleno Therapeutics Inc stock.
You can see the complete history of Anish Anish stock trades at the bottom of the page.
Dr. Anish Bhatnagar M.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Bhatnagar was appointed as our Chief Executive Officer in February 2014. Prior to that, he served as our President and Chief Operating Officer. Dr. Bhatnagar joined us in 2006, and has held positions of increasing responsibility since then. Dr. Bhatnagar is a physician with over 15 years of experience in the medical device and biopharmaceutical industries. His experience spans development of biologics, drugs, drug-device combinations and diagnostic as well as therapeutic medical devices. His prior experience includes working at Coulter Pharmaceuticals, Inc. from 1998 to 2000 and Titan Pharmaceuticals, Inc. from 2000 to 2006. He is the author of several peer-reviewed publications, abstracts and book chapters. He obtained his medical degree at SMS Medical College in Jaipur, India and completed his Residency and Fellowship training in the U.S. at various institutions, including Georgetown University Hospital and the University of Pennsylvania.
As the President, Chief Executive Officer a Director of Soleno Therapeutics Inc, the total compensation of Anish Bhatnagar at Soleno Therapeutics Inc is $822,089. There are no executives at Soleno Therapeutics Inc getting paid more.
Anish Bhatnagar is 52, he's been the President, Chief Executive Officer a Director of Soleno Therapeutics Inc since 2018. There are 7 older and 3 younger executives at Soleno Therapeutics Inc. The oldest executive at Soleno Therapeutics Inc is Ernest Mario, 81, who is the Independent Chairman of the Board.
Bhatnagar's mailing address filed with the SEC is 203 REDWOOD SHORES PKWY, STE 500, , REDWOOD CITY, CA, 94065.
Over the last 9 years, insiders at Soleno Therapeutics Inc have traded over $134,327,999 worth of Soleno Therapeutics Inc stock and bought 56,592,152 units worth $70,324,676 . The most active insiders traders include Advisors Llcperceptive Life..., Jack W Schuler a Andrew Sinclair. On average, Soleno Therapeutics Inc executives and independent directors trade stock every 29 days with the average trade being worth of $36,911,570. The most recent stock trade was executed by Kristen Yen on 28 August 2024, trading 10,705 units of SLNO stock currently worth $507,738.
soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.
Soleno Therapeutics Inc executives and other stock owners filed with the SEC include: